# AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

> **NCT02694822** · PHASE1,PHASE2 · COMPLETED · sponsor: **Agenus Inc.** · enrollment: 89 (actual)

## Conditions studied

- Advanced Solid Cancers
- Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

## Interventions

- **DRUG:** Zalifrelimab

## Key facts

- **NCT ID:** NCT02694822
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-31
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694822, "AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02694822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*